Source: International Congress 2018 – Physiological and biological insights in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Ružicková-Kirchnerová (Pilsen, Czech Republic), P. Molácková (Pilsen, Czech Republic), M. Terl (Pilsen, Czech Republic), P. Vaník (Ceske Budejovice, Czech Republic), P. Panzner (Pilsen, Czech Republic). 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab.. 658

Member's Comments

No comment yet.

Related content which might interest you: ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Follow-up of patients with moderate-severe allergic asthma treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Omalizumab in children with severe persistent allergic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017